MedTrace Logo

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

NCT01240928 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-08-20

No results posted yet for this study

Summary

This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.

Conditions

Interventions

DRUG

MSK-2206

Level 1: MK-2206 135mg weekly

DRUG

Exemestane

Level 1: Exemestane - 25mg daily

DRUG

Goserelin

Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only

Sponsors & Collaborators

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Vandana Abramson, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240928 on ClinicalTrials.gov